RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenesLeona A. Martin, G.G. Li, Sean Uryu et al.|European Journal of Cancer|2016Cited by 0